Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema – Intellia Therapeutics

1. Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema  Intellia Therapeutics
2. Intellia Therapeutics Completes Enrollment in Phase 3 Study of Potential Hereditary Angioedema Treatment  MarketScreener
3. Intellia rises after enrolling patients in late-stage trial of genetic disorder drug  TradingView
4. Gene Editing Breakthrough: Intellia’s HAE Drug Trial Fully Enrolled, Could Transform Rare Disease Treatment  Stock Titan

Continue Reading